Spots Global Cancer Trial Database for yttrium y 90 ibritumomab tiuxetan
Every month we try and update this database with for yttrium y 90 ibritumomab tiuxetan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma | NCT00070447 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... yttrium Y 90 ib... | 18 Years - | National Cancer Institute (NCI) | |
| Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00119392 | B-cell Chronic ... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Waldenström Mac... | rituximab cyclosporine fludarabine pho... mycophenolate m... yttrium Y 90 ib... peripheral bloo... allogeneic hema... total-body irra... | 18 Years - | Fred Hutchinson Cancer Center | |
| Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma | NCT00017381 | Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac... | rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma | NCT00334438 | Lymphoma | rituximab bortezomib yttrium Y 90 ib... Indium 111 ibri... | 18 Years - 120 Years | UNC Lineberger Comprehensive Cancer Center | |
| Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma | NCT00397800 | Lymphoma | rituximab cyclophosphamid... fludarabine pho... yttrium Y 90 ib... | 50 Years - 75 Years | Technical University of Munich | |
| Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia | NCT00060294 | Lymphoma | rituximab yttrium Y 90 ib... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma | NCT00334438 | Lymphoma | rituximab bortezomib yttrium Y 90 ib... Indium 111 ibri... | 18 Years - 120 Years | UNC Lineberger Comprehensive Cancer Center | |
| Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma | NCT00082836 | Lymphoma | rituximab yttrium Y 90 ib... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma | NCT00110149 | Lymphoma | rituximab yttrium Y 90 ib... | 18 Years - 120 Years | Beth Israel Deaconess Medical Center | |
| Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma | NCT00058422 | Lymphoma | darbepoetin alf... filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... indium In 111 i... yttrium Y 90 ib... | 60 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma | NCT01359592 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... R-CHOP regimen laboratory biom... fludeoxyglucose... selective exter... yttrium Y 90 ib... | 18 Years - | SWOG Cancer Research Network | |
| Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma | NCT00058422 | Lymphoma | darbepoetin alf... filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... indium In 111 i... yttrium Y 90 ib... | 60 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL | NCT01686165 | Anaplastic Larg... Recurrent Adult... Recurrent Mantl... | belinostat rituximab yttrium Y 90 ib... | 18 Years - | University of Arizona | |
| Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma | NCT00334438 | Lymphoma | rituximab bortezomib yttrium Y 90 ib... Indium 111 ibri... | 18 Years - 120 Years | UNC Lineberger Comprehensive Cancer Center | |
| Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00012298 | Extranodal Marg... Nodal Marginal ... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Splenic Margina... Waldenström Mac... | rituximab yttrium Y 90 ib... indium In 111 i... oprelvekin filgrastim | 18 Years - | National Cancer Institute (NCI) | |
| Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00033423 | Lymphoma | rituximab yttrium Y 90 ib... | 19 Years - | University of Alabama at Birmingham | |
| Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00033423 | Lymphoma | rituximab yttrium Y 90 ib... | 19 Years - | University of Alabama at Birmingham | |
| Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma | NCT00058422 | Lymphoma | darbepoetin alf... filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... indium In 111 i... yttrium Y 90 ib... | 60 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma | NCT00110149 | Lymphoma | rituximab yttrium Y 90 ib... | 18 Years - 120 Years | Beth Israel Deaconess Medical Center | |
| Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma | NCT00690560 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... yttrium Y 90 ib... | 65 Years - 80 Years | Centre Antoine Lacassagne | |
| Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma | NCT00073957 | Lymphoma | rituximab cytarabine liposomal cytar... yttrium Y 90 ib... | 18 Years - 120 Years | Beth Israel Deaconess Medical Center | |
| Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma | NCT00637832 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisolone vincristine sul... yttrium Y 90 ib... | 18 Years - 120 Years | University of Southampton | |
| Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma | NCT00017381 | Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac... | rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan | NCT00577278 | Graft Versus Ho... Leukemia Lymphoma | rituximab fludarabine pho... melphalan sirolimus tacrolimus allogeneic hema... indium In 111 i... yttrium Y 90 ib... laboratory biom... | 18 Years - 69 Years | City of Hope Medical Center | |
| Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation | NCT00031642 | Lymphoma | rituximab yttrium Y 90 ib... | 19 Years - 120 Years | University of Nebraska | |
| Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma | NCT01973062 | Primary Central... | rituximab yttrium Y 90 ib... | 18 Years - | Case Comprehensive Cancer Center | |
| Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients | NCT00562978 | Lymphoma | filgrastim cyclophosphamid... etoposide AHSCT yttrium Y 90 ib... | 18 Years - 60 Years | City of Hope Medical Center | |
| Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation | NCT00031642 | Lymphoma | rituximab yttrium Y 90 ib... | 19 Years - 120 Years | University of Nebraska | |
| Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder | NCT00064246 | Post-transplant... Recurrent Adult... Recurrent Adult... Stage III Adult... Stage III Adult... Stage IV Adult ... Stage IV Adult ... Waldenström Mac... | rituximab indium In 111 i... yttrium Y 90 ib... | 18 Years - | National Cancer Institute (NCI) | |
| Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00058292 | Lymphoma | filgrastim rituximab Carmustine cytarabine etoposide melphalan peripheral bloo... yttrium Y 90 ib... | 17 Years - | Northwestern University | |
| Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients | NCT00562978 | Lymphoma | filgrastim cyclophosphamid... etoposide AHSCT yttrium Y 90 ib... | 18 Years - 60 Years | City of Hope Medical Center | |
| Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma | NCT00082836 | Lymphoma | rituximab yttrium Y 90 ib... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00033423 | Lymphoma | rituximab yttrium Y 90 ib... | 19 Years - | University of Alabama at Birmingham | |
| S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma | NCT01359592 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... R-CHOP regimen laboratory biom... fludeoxyglucose... selective exter... yttrium Y 90 ib... | 18 Years - | SWOG Cancer Research Network | |
| Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma | NCT00695409 | Lymphoma | rituximab carmustine cytarabine etoposide melphalan ASCT yttrium Y 90 ib... | 18 Years - | City of Hope Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
